• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Gold nanoparticles target chromosomes in cancer cells

November 9, 2016 By Sarah Faulkner

Gold nanoparticles target chromosomes in cancer cellsResearchers tagged gold nanoparticles with a small dose of radiation to trace the particles as they deliver a drug into the heart of a cancer cell, according to work presented at the 2016 National Cancer Research Institute conference.

A team of researchers from the Oxford Institute for Radiation Oncology worked to deliver drugs to the “control room” of cancer cells, where the chromosomes are kept. The drug targets telomerase, the building blocks of telomeres at the end of chromosomes.

“Gold is precious in more than one way. We have used tiny gold nanoparticles loaded with targeted drugs to kill cancer cells in the laboratory,” lead researcher Kate Vallis said in prepared remarks. “Our long term goal is to design new treatments for cancer patients based on this promising approach.”

Telemeres act as timers to ensure cells do not live longer than programmed. Every time a cell divides, telomeres shorten and when it reaches a critical length, the cell can no longer divide and it dies. Cancer cells manipulate this built-in system by reactivating telomerase, which leads to uncontrolled cell proliferation.

Researchers engineered the gold nanoparticles and added a radioactive tracer to prove that the drug was reaching its target in skin cancer cells and turning off telomerase. Once the cancer cells are made more sensitive to radiation, the radioactive tracer can also be used to deliver a dose of radioactivity.

“Gold has been used in medicine for many years and this research adds further insight into its potential,” Cancer Research UK’s chief exec Sir Harpal Kumar added. “Ensuring that treatment is accurately targeted at cancer and avoids healthy cells is the goal for much of cancer research, and this is an exciting step towards that.”

“Research continues to shed light on how cancer cells behave and how to effectively deliver a lethal payload to the tumor.”National Cancer Research Institute director Dr. Karen Kennedy said. “This exciting research offers that potential and needs further investigation to see how it would be used in patients. The future looks exciting with research such as this improving the way the disease is treated.”

Filed Under: Featured, Nanoparticles, Oncology, Pharmaceuticals Tagged With: National Cancer Research Institute, Oxford Institute for Radiation Oncology

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS